We believe developing collaborations and partnerships is a key part of our strategy to successfully leveraging our portfolio of therapeutic products and platform technologies.
In April 29, 2019, Immunomedics and Everest Medicines announce exclusive license agreement for sacitizumab govitecan in East and Southeast Asia excluding Japan.
